ストックスクリーナーアプリを入手
4.36
1.58%
-0.07
アフターアワーズ：
4.44
0.08
+1.83%
前日終値:
$4.43
開ける：
$4.46
24時間の取引高:
942.34K
Relative Volume:
1.98
時価総額：
$257.63M
収益：
$192.64M
当期純損益:
$2.51M
株価収益率:
83.21
EPS:
0.0524
ネットキャッシュフロー:
$12.42M
1週間 パフォーマンス:
+3.81%
1か月 パフォーマンス:
-8.40%
6か月 パフォーマンス:
-1.36%
1年 パフォーマンス:
-15.67%
1日の値動き範囲:
$4.36
$4.46
1週間の範囲:
$4.15
$4.465
52週間の値動き範囲:
$3.8092
$5.545
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
名前
Vanda Pharmaceuticals Inc
セクター
電話
202-734-3400
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.36 | 261.76M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-31 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-25 | ダウングレード | Jefferies | Buy → Hold |
| 2021-05-12 | 開始されました | BofA Securities | Buy |
| 2021-01-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-03-16 | ダウングレード | Oppenheimer | Perform → Underperform |
| 2020-03-12 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-08-01 | アップグレード | Citigroup | Neutral → Buy |
| 2019-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2018-12-04 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 繰り返されました | Jefferies | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-09-21 | 再開されました | Oppenheimer | Outperform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-09-14 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-06-27 | 再開されました | Piper Jaffray | Overweight |
| 2017-05-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Oppenheimer | Outperform |
| 2016-11-09 | 開始されました | Aegis Capital | Buy |
| 2016-10-06 | 再開されました | Jefferies | Buy |
すべてを表示
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
Vanda’s Jet Lag Drug Gets Fresh FDA Look After Court Ruling - Bloomberg Law News
Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionPortfolio Risk Report & Real-Time Market Trend Scan - Newser
Sentiment analysis tools applied to Vanda Pharmaceuticals Inc.2025 Price Momentum & Scalable Portfolio Growth Methods - Newser
Vanda Pharmaceuticals Receives Strong Buy Rating Amidst Growth in Key Product Lines and Promising FDA Decision on Bysanti - AInvest
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
Insider Buying: Mihael Polymeropoulos Acquires Additional Shares of Vanda Pharmaceuticals Inc (VNDA) - GuruFocus
Vanda Pharmaceuticals CEO Buys 10,000 Shares at $4.15/Share on August 7, 2023. - AInvest
Vanda (VNDA) Q2 Revenue Rises 4% - AOL.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Cut to Strong Sell at Wall Street Zen - Defense World
Vanda Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - Jammu Links News
What is the dividend policy of Vanda Pharmaceuticals Inc. stockSuperior returns - Jammu Links News
What makes Vanda Pharmaceuticals Inc. stock price move sharplyCapitalize on high-yield stocks early - Jammu Links News
Is Vanda Pharmaceuticals Inc. stock overvalued or undervaluedCapitalize on emerging growth stocks - Jammu Links News
What are Vanda Pharmaceuticals Inc. company’s key revenue driversRapidly growing investment returns - Jammu Links News
What institutional investors are buying Vanda Pharmaceuticals Inc. stockRapid growth trajectories - Jammu Links News
What catalysts could drive Vanda Pharmaceuticals Inc. stock higher in 2025Unlock your portfolio’s full growth potential - Jammu Links News
Why is Vanda Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize portfolio value with timely trades - Jammu Links News
What are the technical indicators suggesting about Vanda Pharmaceuticals Inc.Maximize your portfolio’s earning power - Jammu Links News
Is Vanda Pharmaceuticals Inc. a growth stock or a value stockDiscover stocks with massive upside potential - Jammu Links News
Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Phenomenal wealth increase - Jammu Links News
How many analysts rate Vanda Pharmaceuticals Inc. as a “Buy”Get professional advice for market timing - Jammu Links News
Vanda Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals 2025 Q2 Earnings Misses Targets as Net Loss Widens 502% - AInvest
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... By GuruFocus - Investing.com Canada
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising Expenses - GuruFocus
Vanda: Q2 Earnings Snapshot - Norwalk Hour
Vanda Pharmaceuticals' Q2 2025: Navigating Contradictions in Bysanti, PONVORY, and DTC Strategies - AInvest
Vanda Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Vanda Pharmaceuticals Q2 2025 misses EPS and revenue forecasts - Investing.com Nigeria
Vanda Pharmaceuticals: Navigating Q2 Earnings Disappointment Amid High-Stakes Pipeline Progress - AInvest
Vanda Pharmaceuticals Sees Strong Fanapt Growth Despite Rising Losses - Finimize
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Q2 2025 Earnings: EPS Misses at -$0.46, Revenue Falls Short at $52.6 Million - GuruFocus
Vanda Pharmaceuticals' Q2 2025 Earnings: A Turning Point in Pipeline Execution and Commercialization - AInvest
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results - ADVFN Brasil
How volatile is Vanda Pharmaceuticals Inc. stock compared to the marketMarket Forecast Data Feed Backed By Experts - jammulinksnews.com
Exploring US High Growth Tech Stocks For Potential Portfolio Expansion - simplywall.st
How Vanda Pharmaceuticals Inc. stock performs during market volatilityExit Ready Momentum Stock Watchlist Expanded - metal.it
Price Channel Expanding on Vanda Pharmaceuticals Inc.’s ChartROI Boosting Trade Opportunity Calendar Published - metal.it
Vanda Pharmaceuticals Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Bronstein, Gewirtz & Grossman, LLC Class Action Update Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH) - ACCESS Newswire
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Vanda Pharmaceuticals Inc (VNDA) 財務データ
収益
当期純利益
現金流量
EPS
Vanda Pharmaceuticals Inc (VNDA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | Director |
Jun 13 '25 |
Sale |
4.59 |
7,000 |
32,130 |
97,082 |
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):